CSTL Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 jul 2024 @ 20:16):
Our systems believe the stock currently is undervalued by 0.03% compare to its pairs and should correct upwards.

Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers...

Stats
Dagens volum	145 363
Gjennomsnittsvolum	240 198
Markedsverdi	589.14M
EPS	$-0.0922 ( Q1 \| 2024-05-02 )
Neste inntjeningsdato	( $0 ) 2024-07-31
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-18.88 (Sector) 42.63 (Industry) 0
ATR14	$0.0250 (0.12%)

ACRS 13.64%

AKU -17.87%

APDN 15.40%

BDSX -1.96%

BIOC 0.00%

BNGO -2.60%

BNR -2.86%

CDNA -0.84%

CEMI 0.22%

CHEK 4.04%

CNTG -0.89%

CSTL -1.98%

DMTK -11.32%

DRIO -5.88%

EXAS 0.17%

FLDM -7.02%

FLGT 0.92%

GENE 0.00%

GH -2.93%

GTH 0.12%

HTGM 0.00%

ICLR 1.11%

IDXX -2.29%

ILMN 0.85%

ISPC -2.76%

LAB -2.26%

LMDX 0.00%

MDXH -2.50%

ME -1.51%

MEDP -0.52%

MYGN -2.37%

MYNZ -16.46%

NDRA -3.83%

NEO 0.72%

NEOG -4.38%

NOTV -5.12%

NTRA -0.52%

OCDX 0.92%

OLK 0.08%

OPGN 0.96%

OPK -2.01%

PMD -2.89%

PRPO 7.19%

PSNL -0.43%

RDNT -1.29%

SERA 2.70%

SHC -2.44%

SQL 0.00%

STIM -0.56%

STRR -4.19%

STRRP -5.05%

SYNH 0.02%

TRIB 3.38%

TTOO 2.06%

TWST 0.64%

VIVO 0.00%

XGN 0.55%

Insider Trading

Date	Person	Action	Amount	type
2024-06-03	Maetzold Derek J	Sell	1 192	Common Stock
2024-06-03	Maetzold Derek J	Sell	20	Common Stock
2024-06-03	Maetzold Derek J	Sell	1 192	Common Stock
2024-06-03	Maetzold Derek J	Sell	20	Common Stock
2024-06-03	Maetzold Derek J	Sell	2 328	Common Stock

INSIDER POWER
44.02
Last 99 transactions
Buy: 431 991 \| Sell: 160 808

Korrelasjon (AI algo v.1.1b): Undervalued: 0.03% $21.34 paired level. (Algoen sporer endringene til de mest korrelerte aksjene i sanntid og gir umiddelbar oppdatering)

Volum Korrelasjon

Lang: -0.33 (neutral)

Kort: 0.06 (neutral)

Signal:(52.407) Neutral

Castle Biosciences Inc Korrelasjon

10 Mest positive korrelasjoner
OZEM	1
NEWZ	0.823

10 Mest negative korrelasjoner
BKHA	-0.89
MNDR	-0.862
GTAPX	-0.83
INDH	-0.807
AGAQX	-0.803

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Castle Biosciences Inc Korrelasjon - Valuta/Råvare

-0.11
( neutral )

-0.09
( neutral )

0.00
( neutral )

0.14
( neutral )

0.51
( weak )

-0.24
( neutral )

Castle Biosciences Inc Økonomi

Annual	2023
Omsetning:	$219.79M
Bruttogevinst:	$164.23M (74.72 %)
EPS:	$-2.14

FY	2023
Omsetning:	$219.79M
Bruttogevinst:	$164.23M (74.72 %)
EPS:	$-2.14

FY	2022
Omsetning:	$137.04M
Bruttogevinst:	$105.03M (76.64 %)
EPS:	$-2.58

FY	2021
Omsetning:	$94.09M
Bruttogevinst:	$78.26M (83.18 %)
EPS:	$-1.237

Financial Reports:

No articles found.

Castle Biosciences Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Castle Biosciences Inc

Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.